Eli Lilly Receives Nod for Innovative Alzheimer's Treatment in India

Eli Lilly and Company (India) has received approval from CDSCO for donanemab, a drug targeting Alzheimer's disease. With its marketing authorization, the drug aims to slow cognitive decline in adults with early-stage Alzheimer's, marking a milestone in addressing dementia needs in India.

In a significant development for Alzheimer's treatment, Eli Lilly and Company (India) announced it has received approval from the Central Drugs Standard Control Organization (CDSCO) for donanemab. This drug targets Alzheimer's disease, specifically focusing on the early symptomatic stages in adults.

Donanemab, administered intravenously every four weeks, aims to slow the progression of cognitive decline by targeting amyloid plaques, a key factor in Alzheimer's. Winselow Tucker, President and General Manager of Lilly India, stated that this approval is a pivotal milestone in supporting those affected by the disease in the country.

With Alzheimer's being the leading cause of dementia worldwide, the need for effective treatments is critical. As per estimates, by 2030, over 8 million individuals in India could be affected by dementia, predominantly due to Alzheimer's. The underdiagnosis of this condition highlights the urgent need for innovative solutions like donanemab.

(With inputs from agencies.)